54 results about "Primary disease" patented technology

A radiation therapy system optimized for treating extremities such as the breast has unique geometrical features that enable the system to deliver an accurately located prescribed dose to a target volume while eliminating or reducing the collateral dose delivered to the rest of the patient. The patient lies in a prone position on a rotating, shielded table, with the anatomy to be treated protruding through an orifice in the table into the path of a radiation beam. An optional integral imaging system provides accurate target volume localization for each treatment session. Utilizing the effects of gravity on a prone patient maximizes the separation of a target volume within the breast to adjacent critical structures such as the chest wall, heart and lungs, thereby reducing long term complications not associated with the primary disease. A shielded interface surface between the radiation source and the patient reduces patient dose due to scattered or stray radiation. A shielded enclosure for the radiation sources combined with the shielded interface surface eliminates the need for primary shielding in the room and allows the therapy system to be used in a transportable, mobile facility.

An object of the present invention is to provide a drug with a high therapeutic or prophylactic effect on dyskinesia, without accompanying aggravation of symptoms of the primary disease, and with fewer side effects.Accordingly, the present invention provides a therapeutic or prophylactic agent for dyskinesia, comprising as an effective component a compound having a 4,5-epoxy morphinan skeleton, which compound is represented by the Formula (I) below, or a pharmaceutically acceptable acid addition salt thereof:[wherein the double line composed of a dashed line and a solid line represents a double bond or single bond, R1 is C4-C7 cycloalkylalkyl, R2 is C1-C5 straight or branched alkyl, and B is —CH═CH—.]

The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile, or to both toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for neutralizing the toxins from C. difficile, thus providing a means of treating the disease and symptoms associated with a C. difficile infection, including the treatment of diarrhea, or pseudomembranous colitis caused by C. difficile. The antibodies may also prevent the severity and / or duration of the primary disease, or may prevent the number, duration, and / or the severity of recurrences, or relapses of the disease attributed to the presence of C. difficile. The antibodies of the invention may also be useful for diagnosis of an infection by C. difficile.

Speciated antibodies or antigen-binding fragments that bind staphylococcal antigens are provided, where the antibodies and antigen-binding fragments have attenuated Fc binding to Protein A or homologous protein. Compositions comprising the antibodies and methods of use are also provided. The antibodies and compositions are useful for treating staphylococcal infection, reducing serum or kidney bacterial titers, and treating symptoms associated with staphylococcal infection. The antibodies may also prevent the severity and / or duration of the primary disease.

The invention provides an external-use medicine composition for treating eruption and a preparation method and application of the composition. The external-use medicine composition is prepared from the following raw medicines in parts by weight: 20 to 40 parts of rosin, 20 to 40 parts of indigo naturalis, 14 to 26 parts of cuttle bone, 14 to 26 parts of sulfur and 14 to 26 parts of alomel. The invention also provides a preparation method and application of the medicine composition. The medicine composition can effectively eliminate or greatly relieve symptoms of eruption diseases such as eczema and prurigo by an external treatment method and can eliminate influence of a source of the disease caused by hypersensitivity to a certain extent; the primary disease can be treated; and a new selection is supplied to clinical medicine use.